Nasdaq has informed the Company that it must present its views to Nasdaq with respect to this deficiency in writing by April ...

Summary: Myriad's Precise MRD test is an ultrasensitive second-generation hybrid-capture-based tumor-informed assay that ...

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 ...

As a result, the total number of registered shares as set forth in the Company's Articles of Association has increased to ...

PIRAEUS, Greece, April 25, 2025 (GLOBE NEWSWIRE) -- Navios Maritime Partners L.P. ("Navios Partners”) (NYSE:NMM) announced today that its Board of Directors has declared a cash distribution of $0.05 ...

First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co-development with Orano Med "Our presentations at AACR highlight the breadth of Molecular Partners' DARPin ...

The Company has received approval from the TSXV for an amendment to the terms of the Eligible Warrants to enable holders thereof who elect to exercise their Eligible Warrants, at the price of $0.09 on ...

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the presentatio ...

In the Acceptance Letter, NYSE American granted the Company until August 3, 2026 (the "Plan Period”) to regain compliance with the continued listing standards. During the Plan Period, the Company will ...

Interested parties in the United States and Canada may participate toll-free by dialing (833) 816-1385. International parties may participate by dialing (412) 317-0478. Participants should ask to be ...

With the FDA's push to adopt and validate New Approach Methodologies (NAMs) under the FDA Modernization Act 2.0, Spanios and ...

What collagen is and how it naturally declines with age, contributing to common aging concerns Why hydrolyzed grass-fed ...